Articles tagged with Gastrointestinal Neoplasms
Researchers have made significant progress in using immunotherapies prior to surgery, leading to better biomarkers and more effective combination therapies. This approach has shown promise in various cancer types, including lung cancer, triple-negative breast cancer, melanoma, and gastrointestinal cancers.
A new targeted treatment called zolbetuximab has been shown to extend survival for patients with advanced gastric or gastroesophageal junction cancer that overexpresses a specific biomarker. The treatment significantly increased progression-free and overall survival, with improved results compared to standard chemotherapy.
Early-onset cancer incidence rates among people under 50 increased significantly between 2010 and 2019, with breast cancer leading the number of cases. Gastrointestinal cancers showed the highest growth rate in this age group, highlighting the need for targeted surveillance strategies and funding priorities
A large long-term study found that good cardiorespiratory fitness in young men is associated with a significantly lower risk of developing nine specific cancers, including a 40% reduced risk of liver cancer. Higher fitness was also linked to lower risks of rectal, pancreatic, and bowel cancers.
Researchers have developed a new gene-editing tool that enables the precise study of single-base mutations in cancer-causing genes. This technology allows for detailed experiments in tissues, which may lead to better understanding of genetic changes influencing patient response to cancer therapies.
A large clinical trial found that surgery does not increase the number of days patients with advanced cancer are alive and out of the hospital, but improves symptoms and quality of life. Patients who underwent surgery reported fewer bowel-related symptoms after leaving the hospital.
Recent studies in the New Journal of Pharmaceutical Analysis feature novel diagnostic tools, RNA sequencing-based workflows, and mechanical property evaluations to enhance cancer and cardiovascular disease treatment outcomes. These innovations aim to improve the therapeutic effect of drugs and promote personalized medicine.
A preclinical study has uncovered the role of Y chromosome gene KDM5D in regulating anti-tumor immune responses and promoting metastasis in male patients with KRAS-mutated colorectal cancer. The study reveals that mutant KRAS drives upregulation of KDM5D, leading to reduced cell adhesion and immune recognition by the immune system.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
A Phase II trial led by MD Anderson Cancer Center showed that zanidatamab achieved a 41% confirmed objective response rate and durable responses in HER2-positive biliary tract cancer. This represents the largest study of a HER2-targeted drug in BTC, providing evidence for its potential as a new treatment option.
Researchers at West Virginia University found that bariatric surgery significantly reduces the risk of major cardiovascular events and death in patients with NAFLD. The study included 9,374 adult patients with NAFLD and obesity, who underwent either Roux-en-Y gastric bypass or sleeve gastrectomy.
The study revealed lower age-standardized rate of NENs incidence in China (1.14 per 100,000) compared to the USA (6.26 per 100,000). The most common sites for primary NEN tumors progressed were found to be the pancreas, stomach, lungs, and rectum.
Jeong Min Lee, KSR President and professor at Seoul National University Hospital, is honored with ARRS membership. He has published over 470 scientific articles and serves on the editorial board of several publications.
A study led by Tokyo University of Science researchers identified Dectin-1's role in promoting colorectal cancer by enhancing PGE2 production and suppressing IL-22BP expression. The study used mouse models and clinical samples to validate the findings, which have immediate clinical implications for CRC patients.
A study found that prenatal exposure to the anti-nausea drug Bendectin, containing dicyclomine, increased the risk of colorectal cancer in adult offspring. Incidence rates were three times higher among exposed children compared to those not exposed.
Researchers found that excessive iron absorption by tumor cells drives colorectal cancer growth, and a specific gene pathway is key. Inactivating this pathway can extend animal survival and potentially be used to treat cancer.
Studies elucidate key aspects of traditional Chinese compounds and modern cancer therapeutics, highlighting the efficacy of R. serra in treating colitis and identifying active components of Gan Cao in treating pneumonia. A new radiolabeled antibody-based probe for detecting PD-L1 expression in cancers also provides a novel approach to ...
Researchers explore CEACAM1, CEACAM5, and CEACAM6's pathological significance in cancer biology and immunology. The review highlights their interactions with pathogens and potential avenues for cancer therapy.
Researchers at Uppsala University developed a prognostic method using a combination of immune cells to provide clearer disease prognoses and predict which patients will respond best to immunotherapy. The method was shown to be associated with patient fate in several types of cancer.
A Phase 3 clinical trial has shown that a four-drug chemotherapy regimen significantly increases overall survival and progression-free survival in patients with stage 4 pancreatic ductal adenocarcinoma. The study's results suggest that this more aggressive treatment approach may be considered for eligible patients.
A phase 3 trial found that adding nab-paclitaxel to a standard gemcitabine plus cisplatin regimen did not significantly extend median overall survival for patients with advanced biliary tract cancers, but provided benefits for subsets of patients. The treatment also showed improved response rates and progression-free survival times.
Researchers developed predictive models using serum microRNAs to identify patients at risk of requiring early palliative care. The study used serum samples from 178 patients with various types of cancer and found that miRNA-based models had higher accuracy than clinical models in predicting referral to a palliative care unit.
Researchers highlight recent progress in organotypic models, which offer a balance between the accessibility and control of in vitro context. These models have been used to study various aging-related phenotypes, including skin, gut, and skeletal muscle, providing valuable insights into the underlying mechanisms.
Researchers at VHIO have established a unique collection of metastatic cholangiocarcinoma patient-derived xenografts to help prioritize potential clinical trials and deliver precision patient care. The models have identified mutations in genes such as BRCA2, which could serve as a biomarker for response to PARP inhibitors.
A global study found that early-stage mucinous ovarian cancer patients with an infiltrative pattern of invasion have poorer survival chances. This discovery could lead to more targeted treatment strategies for these patients. Researchers hope to develop targeted drugs and align treatment guidelines worldwide.
Researchers found that certain fungal species in tumors are linked to inflammation and reduced cell-to-cell adhesion, features associated with late-stage cancer spread. High levels of these fungi may serve as biomarkers for metastasis risk and lead to more effective treatment choices.
A novel PET radiotracer has been developed to assess tumor aggressiveness in neuroendocrine neoplasms, providing valuable information for personalized care. High uPAR expression was associated with a worse prognosis, making it a potential target for therapy.
The TTUHSC team will provide no-cost colorectal cancer screening and colonoscopies to underinsured and uninsured people living in South Plains region counties. The FIT-STOP program aims to find signs of early-stage colorectal cancer to prevent treatment needs, leveraging existing relationships with partners.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
Researchers at Johns Hopkins Medicine found that Clostridioides difficile (C. difficile) bacteria may cause colorectal cancer in younger adults. The bacterium causes serious diarrheal infections and is linked to approximately 500,000 infections annually in the US.
A new study found that circulating tumor DNA can identify stage II colon cancer patients who benefit from chemotherapy, sparing others the need for treatment. The study showed reduced use of chemotherapy without compromising survival rates.
Researchers at Weill Cornell Medicine found that tumors recruit nearby cells called fibroblasts to work as their enablers by releasing lactate. This finding suggests that future drug treatments could target this defense mechanism to help cancer patients.
Researchers at CU Anschutz Medical Campus discovered a reactivated protein, Hand2, in certain cases of mesothelioma, which may lead to new treatments. The study aims to investigate the cause and effect of this reactivation.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
Researchers have created a new type of colon tattoo ink that is more biocompatible and less prone to diffusion than existing inks. The ink uses metal-derived nanoparticles and polymers to adhere to the submucosal surface in the colon, allowing for better identification and removal of complex polyps and tumors.
Scientists have discovered a new therapeutic approach to aid the immune system in fighting cancer, offering hope for better solutions for patients. Researchers found that blocking the EP4 molecule can 'free' the immune system and restore its cancer-fighting functions.
A comprehensive analysis of over 2,200 patients in Europe reveals the complexity of cholangiocarcinoma, a rare cancer often diagnosed at an advanced stage. The study highlights the need for education programs to raise awareness and improve early diagnosis, survival, and quality of life.
A recent study published in Developmental Cell reveals that Kras mutation causes chromatin rearrangement, leading to stem-like cell regeneration and tumor onset. The team discovered a protein complex called AP-1 as the mediator of this process, which can be targeted with small-molecule drugs.
A large study analyzed administrative health data from Ontario and found a low risk of major anomalies with tramadol and morphine, minor anomalies with codeine, hydromorphone, and oxycodone exposure. The study highlights the need to consider both the benefits and harms of opioid treatment during pregnancy.
Researchers discovered a bacterial toxin that can accelerate colon cancer in mice, sharing similarities with human tumors. The study's findings suggest a potential link between transient food poisoning and colorectal cancer development, highlighting the need for further epidemiological studies.
Researchers have discovered that intestinal bacteria can lead to more severe adhesions after abdominal surgery. The study found that mesothelial cells and EGFR signaling play a crucial role in the formation of these adhesions. The findings suggest that targeting EGFR may be a potential approach to reducing adhesion risk.
A new type of PRRT, <sup> 177 </sup> Lu-DOTA-LM3, has been shown to be safe and effective in treating neuroendocrine neoplasms. The therapy achieved complete remission in some patients and was well-tolerated by most patients.
Researchers compared the accuracy of two types of fecal tests for detecting colorectal cancer, finding that both types are reliable when thresholds are adjusted. The study suggests that health providers should select the best type of test based on specific demands in screening settings.
Researchers at MIT have developed a new diagnostic nanoparticle that can detect cancerous proteins in urine and pinpoint tumor locations. This technology has the potential to monitor tumor recurrence after treatment or perform routine cancer screenings, potentially leading to earlier detection and improved patient outcomes.
Scientists have found that short-chain fatty acids can increase the efficiency of tumor therapies by boosting the activity of killer cells. The researchers identified pentanoate, produced by Megasphaera massiliensis bacteria, as a key player in this process.
Researchers found that 14-3-3sigma acts as a tumor suppressor in the gastrointestinal tract, inhibiting cell division and DNA damage repair. Its expression is downregulated in metastatic tumors and low levels correlate with worse prognosis.
A study published in Cancer Cell found that cavity-resident macrophages express high levels of Tim-4, which interacts with CD8+ T cells, distracting them from attacking tumors. Blocking Tim-4 enhances the effectiveness of immunotherapies and improves outcomes in mouse models of cancer.
Researchers discovered that MAOIs can activate the immune system to shrink various types of tumors. The study found that MAOIs help block immune checkpoints and prevent tumor-associated macrophages from suppressing T cell activity.
A new Arizona State University study has shown that high fat diets can trigger a molecular cascade of events leading to colon cancer through intestinal stem cells. The research found that PPARs, specifically PPAR delta and alpha, play a crucial role in elevating cancer risk by stimulating the metabolism of fats.
A Ludwig Cancer Research study has discovered how to revive terminally exhausted T lymphocytes, found within tumors, for cancer therapy by using an immune factor called interleukin-10. This revival restores their potent anti-cancer activity, leading to tumor regression and cures in mouse models of melanoma and colon cancer.
A new test, called Guardant Reveal, can detect residual cancer DNA in the blood of patients after treatment without knowing the specific mutations present in their tumor. The study found that this approach was similar in sensitivity and specificity to traditional methods.
The study identified several cellular pathways that change when a tumor becomes aggressive, and developed a simple system to model their effect. The model integrated different types of experimental data, including transcription factors, to predict which targets are important for colorectal cancer aggressiveness.
Researchers have developed a lower-dose radiopharmaceutical that improves treatment efficacy for neuroendocrine cancers while reducing side effects. The new medication uses reversible binding technology to extend its half-life in the blood, providing an extended therapeutic time window and improved treatment outcomes.
Researchers developed a second window ICG technique to identify brain metastases during surgery, predicting gross-total resection and progression-free survival. The technique achieved high accuracy in distinguishing tumors from healthy brain tissue.
Research at University of California San Diego School of Medicine identified a new cellular target for GIST therapy that could lead to improved disease control and cure rates. The study found that specific cell-to-cell communication influences GIST biology and is strongly associated with cancer progression and metastasis.
A phase 2 clinical trial using a personalized treatment approach found increased survival rates among patients with metastatic tumors in gastroesophageal cancers. The study used genetic profiling to tailor treatments, resulting in a 66% one-year survival rate and a median survival time of 15.7 months.
Researchers discovered that the cancer stem cells' ability to form tumors is regulated by a molecular switch called Mll1. Blocking this enzyme can specifically target cancer stem cells, offering hope for more effective treatments. Clinical trials are underway to evaluate the use of Mll1 inhibitors in head and neck tumors.
Researchers have identified a gene, VSIG1, that prevents the development of metastatic tumour cells, enabling targeted therapies to be developed. The study validates the use of spiked-scRNAseq technology for testing drugs against metastases, including personalized approaches.
Researchers found that miR-133b levels were significantly lower in FAP-associated Desmoid tumors than in sporadic Desmoid tumors, while SIRT1 mRNA levels were up-regulated. A negative correlation between miR-133b and SIRT1 was observed, suggesting a novel mechanism underlying progression of FAP-associated Desmoid tumor.
Researchers discovered that nicotinamide riboside (NR) improves the fitness and function of T lymphocytes, which are vital for attacking tumors. In mouse models of melanoma and colon cancer, NR enhanced anti-tumor activity by improving mitochondrial function and preventing exhaustion.